A study was carried out in which the platelet count was decreased in approximately half the patients with hyperthyroidism and gradually increased with treatment. Platelet disappearance curves were curvilinear and the platelet survival was shortened in the hyperthyroid state. Patients maintained in a euthyroid state for 3 months or less continued to have a shortened platelet survival. The survival returned to normal after 6 months or more of euthyroid status. In order to clarify the cause of the decreased platelet count in the patients, animal experiments were performed. T3-injected rats had decreased platelet counts and shortened platelet survival. When platelets obtained from T3-injected rats were transfused to a control group of untreated rats, the platelet survivals were normal. When platelets obtained from the control group of rats were transfused to T3-injected rats, the platelet survivals were shortened. Disappearance of heat-damaged RBC from the circulation was also accelerated in T3-injected rats. This suggests that thrombocytopenia in Graves’ disease is caused by an increased sequestration potency of the reticulo-endothelial phagocyte system stimulated by thyroid hormone.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.